Dupilumab for Airway Hyper-responsiveness in Asthma with T2 Signature

Phase 3, randomised, double-blind trial in asthma comparing Dupilumab with Matched Placebo (2 arms). Primary endpoint: Proportion of patients that achieve at least one doubling dose improvement in PC20 methacholine and/or a 50% reduction in FEV1 reversibility after bronchodilator at 16 weeks. Started Jul 2019; status: completed.